Premium
Models used to assess cardiovascular function in general pharmacology
Author(s) -
Bunting Patricia B.,
Siegl Peter K. S.
Publication year - 1994
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430320410
Subject(s) - medicine , mechanism (biology) , drug , drug action , pharmacology , mechanism of action , action (physics) , function (biology) , blood pressure , neuroscience , intensive care medicine , bioinformatics , risk analysis (engineering) , psychology , biology , physics , philosophy , biochemistry , epistemology , quantum mechanics , evolutionary biology , in vitro
In the drug developmental process, information obtained from General Pharmacology assays plays an integral part in determining the future direction of the development. The evaluation of a drug in models of cardiovascular function can provide crucial data on cardiovascular activity unrelated to the drug's principal pharmacological action. These data can guide decision‐making steps in safety assessment and clinical studies and address problematic issues from regulatory agencies. While in‐depth protocols are necessary at times, in most instances examination of basic cardiovascular parameters (e.g., blood pressure, heart rate, and electrocardiogram) as well as evaluation of cardiovascular responses to selected autonomic nervous system stimulants, will reveal unpredicted pharmacological activities altering cardiovascular function and provide insight into mechanism of action. Through careful design of an appropriate protocol and animal model, detection of undesired cardiovascular activity can be simply and efficiently achieved.